OTC · Biotechnology

Intellipharmaceutics International Inc. (IPCIF) Stock

$0.15 OTC: IPCIF Healthcare

Intellipharmaceutics International Inc. operates as a pharmaceutical firm primarily engaged in the research, development, and manufacturing of both novel and generic oral solid dosage medications that feature controlled and targeted release mechanisms.

Valuation

MetricValue
Price$0.15
Market Cap$4.96M
P/E Ratio-1.72
P/B Ratio-0.47
P/S Ratio75.52
EPS (TTM)$-0.09
52-Week High$0.15
52-Week Low$0.15
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE27.35%
ROA-201.98%
ROCE26.95%
Gross Margin100.00%
Operating Margin—
Net Margin—
Debt/Equity-0.22
Current Ratio0.04

Annual Financials (USD)

Metric20192020202120222023
Revenue$2.0M$1.0M$1.0M$0$0
Operating Profit$-13.0M$-5.0M$-4.0M$-3.0M$-3.0M
Net Profit$-14.0M$-3.0M$-5.0M$-3.0M$-3.0M
EPS$-2.88$-0.16$-0.22$-0.10$-0.09
Op Margin-778.1%-333.8%-297.8%-4336.8%-4336.8%

Balance Sheet (USD)

Metric20192020202120222023
Total Assets$11.0M$3.0M$2.0M$1.0M$1.0M
Total Liabilities$7.0M$10.0M$10.0M$12.0M$12.0M
Cash$7.0M$0$1.0M$0$0
Borrowings$2.0M$2.0M$2.0M$2.0M$2.0M

Latest News

Hyundai Motor reports 21% drop in Q2 operating profit, misses forecasts Reuters · Jul 23, 2026 Asian stocks rise as AI capex ramps up, oil at six-week highs Reuters · Jul 23, 2026 TenPay Global Named to CNBC's World's Top Fintech Companies 2026 List PR Newswire · Jul 23, 2026 Besi posts sharp rise in quarterly orders Reuters · Jul 23, 2026 Nokia provides recast comparative financial information reflecting the presentation of Fixed Wireless Access CPE and Enterprise Campus Edge businesses as discontinued operations GlobeNewswire · Jul 23, 2026

Cash Flow (USD)

Metric20192020202120222023
Operating Cash Flow$-13.0M$0$-2.0M$-1.0M$-1.0M
Investing Cash Flow$0$0$0$0$1.0M
Financing Cash Flow$-2.0M$1.0M$0$-3.0M$0
Net Cash Flow$5.0M$0$1.0M$-1.0M$-1.0M
Free Cash Flow$-13.0M$0$-2.0M$-1.0M$-1.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.02
EV / EBITDA-2.73
FCF Yield-27.97%
Quick Ratio0.04
Interest Coverage-9.77
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACRDFAcreage Holdings, Inc. $0.12 +2.52% -0.01 $4.88M 0.00%
ACRHFAcreage Holdings, Inc. $0.00 — -0.01 $4.88M 0.00%
BRRGFBerGenBio ASA $97.09 +0.00% -1.26 $9.49B 0.00%
CHNCChina Infrastructure Construction Corp. $0.00 — 0.03 $5.04M 0.00%
DOGPDogecoin Cash, Inc. $0.01 +5.06% 0.12 $1.35M 0.00%

About Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc. operates as a pharmaceutical firm primarily engaged in the research, development, and manufacturing of both novel and generic oral solid dosage medications that feature controlled and targeted release mechanisms. The company's U.S. operations are central to its work. Leveraging its unique and patented Hypermatrix technology, Intellipharmaceutics is dedicated to creating advanced drug delivery systems and cultivating a robust pipeline of product candidates across various therapeutic domains. These include critical areas such as neurological disorders, cardiovascular health, gastrointestinal conditions, diabetes, and pain management. The company's current commercial portfolio includes a variety of extended-release and delayed-release products. These offerings address conditions like hyperactivity disorder (Focalin XR), epilepsy (Keppra XR, Lamictal XR), depression (Effexor XR, Pristiq, Seroquel XR), gastroesophageal reflux disease (Protonix), type 2 diabetes (Glucophage XR), schizophrenia and bipolar disorder (Seroquel XR), heart failure and hypertension (Coreg CR), and chronic angina (Ranexa). Additionally, Intellipharmaceutics is actively progressing several developmental compounds, such as an oxycodone hydrochloride controlled-release capsule (OxyContin) for pain management and a pregabalin extended-release capsule (Regabatin XR) designed for neuropathic pain. The company has established a licensing and commercialization partnership with Par Pharmaceutical Inc. Established in 1998, Intellipharmaceutics International Inc. is based in Toronto, Canada.

Intellipharmaceutics International Inc. is headquartered in CA.

Intellipharmaceutics International Inc. (IPCIF) stock trades at $0.15 with a market capitalization of $4.96M. The stock is valued at a price-to-earnings (P/E) ratio of -1.72, price-to-book of -0.47, price-to-sales of 75.52. Over the past 52 weeks the stock has ranged between $0.15 and $0.15, and currently trades at its 52-week high.

On profitability, Intellipharmaceutics International Inc. generates a return on equity (ROE) of 27.35% — well above the market average, a sign of a high-quality business, return on capital employed of 26.95%.

Official website: www.intellipharmaceutics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides